Successful Collaboration between U.S. Army and Intercell Towards a Novel Vaccine Against Japanese Encephalitis for Military and Travelers

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies

Wien (euro adhoc) - Washington, DC and Vienna, Austria, December 20,
2007 - Today, December 20, 2007 Intercell AG (VSE, "ICLL") announced
the finalization of the submission of a Biologics License Application
(BLA) with the U.S. Food and Drug Administration (FDA) for
Intercell´s investigational Japanese Encephalitis (JE) vaccine.

Intercell´s JE vaccine was developed for over 10 years under a
Collaborative Research and Development Agreement (CRADA) with the
Walter Reed Army Institute of Research (WRAIR). As JE is a
significant and serious public health threat in Asia, the initial
target for use of Intercell´s vaccine will be military personnel and
adult civilian travelers who are deployed to or visit affected
countries, including India, China, and Southeast / Southwest Asia.
Assuming review and approval by the regulatory authorities in a
timely manner, Intercell currently anticipates first market launch of
its JE vaccine during second half of 2008.

"The Army has enjoyed an excellent and successful collaboration with
Intercell for several years towards development of this important JE
vaccine," said William Howell, Acting Director of USAMRMC. "We are
extremely pleased that Intercell´s JE vaccine has progressed to the
point of completion of the BLA submission process. Furthermore, the
timing of this FDA submission is good news because production has
been halted for the only JE vaccine licensed in the United States
today. The Army is hopeful that Intercell´s JE vaccine will be FDA
approved and available for military use in the near future."

"Intercell is greatly appreciative of the expert technical support
the Company has received from the Army during development," noted
Gerd Zettlmeissl, Chief Executive Officer of Intercell.

"We would like to especially thank the many dedicated scientists at
WRAIR for their outstanding efforts. The success of our new JE
vaccine is an excellent example what can be achieved when industry
and government work together towards an important common goal.
Intercell looks forward to the time when we will begin supplying the
novel product for use in the military´s JE immunization program."

About Intercell´s investigational JE vaccine

Intercell´s novel investigational JE vaccine is a purified,
inactivated vaccine for active immunization against the Japanese
Encephalitis virus. With over 3 billion people living in endemic
areas, Japanese Encephalitis, a mosquito-borne flaviviral infection,
is the leading cause of childhood encephalitis and viral encephalitis
in Asia.

In successfully concluded pivotal non-inferiority Phase III trials,
Intercell´s Japanese Encephalitis vaccine demonstrated a favorable
safety and immunogenicity profile:

» The immunogenicity was comparable to that of the U.S. licensed
product, JE- VAX® » It demonstrated an overall clinical safety
profile similar to placebo » Further, Intercell´s JE vaccine showed
an excellent local tolerability profile in this head-to-head study
with JE-VAX®

Intercell´s novel investigational JE vaccine, manufactured in the
company´s proprietary manufacturing facility, is prepared using
tissue culture rather than live organisms and does not contain any
stabilizers such as gelatin or preservatives in its formulation.

On June 13, 2006, Novartis and Intercell announced that the companies
had reached an agreement for Novartis to acquire marketing and
distribution rights for Intercell´s Japanese Encephalitis Virus
Vaccine in the United States, Europe and certain other markets in
Asia and Latin America.

About U.S. Army Medical Research and Material Command

The US Army Medical Research and Materiel Command (USAMRMC) has the
accountability to provide medical materiel and information in support
of the Army´s deployed force. Infectious diseases are of significant
interest as endemic diseases in areas of potential deployment act as
threats to military readiness. Historical data clearly shows that
infectious disease remains one of the primary sources of
hospitalization for soldiers during times of war or military
operations. In response, the Walter Reed Army Institute of Research,
a subordinate command within USAMRMC, has worked vaccine constructs
to several diseases found throughout the world, to include Japanese
Encephalitis. The USAMRMC is pleased that their initial work has led
to the maturation of the technology into the current vaccine being
submitted for licensure. With a successful approval of the
submission, the services will again have a reliable source of vaccine
for their service members.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: LMalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market